AbCellera FY2022 revenue $485M, net income $158.5M; 23 new partnered programs started

AbCellera Biologics Inc.

2022-FY EPS reported $0.50 revenue$485,424,000

Total revenue $485.4M (up 29% YoY); net income $158.5M ($0.50 diluted EPS) vs $153.5M ($0.48 diluted) in 2021.
Royalties from COVID antibodies bamlanivimab/bebtelovimab were $443M; EUA for bebtelovimab suspended in Q4.
Partnership business: 23 new program starts, cumulative 101; 174 programs under contract with 40 partners.
Q4 net loss $29.9M; cash and marketable securities $886.5M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AbCellera Biologics Inc. reported the year ended December 31, 2022 results: revenue $485.4 million in total revenue, net income $158.5 million, or $0.56 per share on a basic and $0.50 on a diluted basis, EPS $0.56 per share on a basic and $0.50 on a diluted basis.

Period: the year ended December 31, 2022
Revenue: $485.4 million in total revenue
Net income: $158.5 million, or $0.56 per share on a basic and $0.50 on a diluted basis
EPS: $0.56 per share on a basic and $0.50 on a diluted basis
Result: reported results

Exact text from the filing

as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- abcl-ex991_43.htm Exhibit 99.1 NEWS RELEASE AbCellera Reports Full Year 2022 Business Results 02/21/2023 • Total revenue of $485 million, compared to $375 million in FY 2021 • Total cumulative partnered program starts of 101, with 23 new starts in the year • Net earnings of $0.56 per share on a basic and $0.50 on

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

AbCellera Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001564590-23-002126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.